Skip to main navigation
  • Investor Home
  • News & Presentations
    News Events Presentations
  • Governance
    Governance Overview Board of Directors Leadership Our ESG Philosophy
  • Financials
    SEC Filings Quarterly Results Annual Reports
  • Stock Information
    Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage
  • Resources
    Pipeline Investor FAQs Email Alerts Contact IR

Presentations


Featured Presentation

Arcutis Fourth Quarter 2025 Financial Results & Business Update 1.6 MB
Arcutis January 2026 Corporate Presentation 1.8 MB
October 27, 2025
Arcutis Investor Day and Third Quarter 2025 Financial Results
January 22, 2024
Arcutis Biotherapeutics ZORYVE (roflumilast) Foam Presentation
December 15, 2023
Arcutis ZORYVE Foam FDA Approval Presentation
October 19, 2023
ARQT October 2023 Corporate Overview
September 19, 2023
Arcutis Biotherapeutics Provides Positive Atopic Dermatitis Program Updates Presentation
December 12, 2022
Arcutis BioTherapeutics Phase 3 Atopic Dermatitis Topline Data Presentation
August 1, 2022
Arcutis ZORYVE FDA Approval Presentation
June 14, 2022
Seborrheic Dermatitis Phase 3 STRATUM Topline Presentation
March 28, 2022
Arcutis Investor Day Presentation
February 1, 2021
DERMIS-1/DERMIS-2 Phase 3 Plaque Psoriasis Topline Data Review
  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Print Page
RSS Feeds
Email Alerts
Search
Arcutis Biotherapeutics logo

© 2026 Arcutis Biotherapeutics, Inc. All rights reserved.

  • Image of the Linkedin Logo
  • Image of the Twitter Logo
  • Image of the Instagram Logo
  • Contact
  • Legal Disclaimer
  • Privacy Notice
  • Consumer Health Data Privacy Policy
  • Your Privacy Choices
  • Cookies Settings

© 2026 Arcutis Biotherapeutics, Inc. All rights reserved.